Thiazolidinediones and cardiovascular disease

Dubois M, Pattou F, Kerr-Conte J, et al.: Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. Diabetologia 2000, 43:1165–1169. Chinetti G, Griglio S, Antonucci M, et al.: Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998, 273:25573–25580. Ricote M, Huang J, Fajas L, et al.: Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1998, 95:7614–7619. Marx N, Sukhova G, Murphy C, et al.: Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 1998,153:17–23. Clark RB, Bishop-Bailey D, Estrada-Hernandez T, et al.: The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol 2000, 164:1364–1371. Padilla J, Kaur K, Harris SG, Phipps RP: PPAR-gamma-mediated regulation of normal and malignant B lineage cells. Ann N Y Acad Sci 2000, 905:97–109. Delerive P, Martin-Nizard F, Chinetti G, et al.: Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circulation 1999, 85:394–402. Marx N, Sukhova GK, Collins T, et al.: PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999, 99:3125–3131. Marx N, Bourcier T, Sukhova GK, et al.: PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 1999, 19:546–551. Law RE, Goetze S, Xi XP, et al.: Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 2000, 101:1311–1318. Marx N, Schonbeck U, Lazar MA, et al.: Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circulation 1998, 83:1097–1103. Chinetti G, Gbaguidi FG, Griglio S, et al.: CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 2000, 101:2411–2417. Martens FM, Visseren FL, Lemay J, et al.: Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002, 62:1463–1480. Ricote M, Li AC, Willson TM, et al.: The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391:79–82. Chinetti G, Fruchart JC, Staels B: Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000, 49:497–505. Pasceri V, Wu HD, Willerson JT, Yeh ET: Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000, 101:235–238. de Dios ST, Bruemmer D, Dilley RJ, et al.: Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation 2003, 107:2548–2550. Bruemmer D, Berger JP, Liu J, et al.: A non-thiazolidinedione partial peroxisome proliferator-activated receptor gamma ligand inhibits vascular smooth muscle cell growth. Eur J Pharmacol 2003, 466:225–234. Wakino S, Kintscher U, Kim S, et al.: Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1→ S transition in vascular smooth muscle cells. J Biol Chem 2000, 275:22435–22441. Jiang C, Ting AT, Seed B: PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391:82–86. Moore KJ, Rosen ED, Fitzgerald ML, et al.: The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med 2001, 7:41–47. Ricote M, Huang JT, Welch JS, Glass CK: The peroxisome proliferator-activated receptor (PPARgamma) as a regulator of monocyte/macrophage function. J Leukocyte Biol 1999, 66:733–739. Mehta JL, Hu B, Chen J, Li D: Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation. Arterioscler Thromb Vasc Biol 2003, 23:2203–2208. Ishibashi M, Egashira K, Hiasa K, et al.: Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 2002, 40:687–693. Li D, Saldeen T, Romeo F, Mehta JL: Oxidized LDL upregulates angiotensin II type 1 receptor expression in cultured human coronary artery endothelial cells: the potential role of transcription factor NF-kappaB. Circulation 2000, 102:1970–1976. Li AC, Binder CJ, Gutierrez A, et al.: Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest 2004, 114:1564–1576. Wang N, Lan D, Chen W, et al.: ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci U S A 2004, 101:9774–9779. Libby P, Ridker PM: Novel inflammatory markers of coronary risk: theory versus practice. Circulation 1999, 100:1148–1150. Plutzky J: Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol 2001, 88:10K-15K. Ridker PM, Rifai N, Rose L, et al.: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347:1557–1565. Ridker PM, Glynn RJ, Hennekens CH: C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998, 97:2007–2011. Barzilay JI, Abraham L, Heckbert SR, et al.: The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001, 50:2384–2389. Haffner SM, Greenberg AS, Weston WM, et al.: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002, 106:679–684. Mohanty P, Aljada A, Ghanim H, et al.: Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004, 89:2728–2735. Festa A, D’Agostino R Jr, Howard G, et al.: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000, 102:42–47. Ghanim H, Garg R, Aljada A, et al.: Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 2001, 86:1306–1312. Aljada A, Garg R, Ghanim H, et al.: Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? J Clin Endocrinol Metab 2001, 86:3250–3256. Bots ML, Hoes AW, Koudstaal PJ, et al.: Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997, 96:1432–1437. O’Leary DH, Polak JF, Kronmal RA, et al.: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999, 340:14–22. Touboul PJ, Elbaz A, Koller C, et al.: Common carotid artery intima-media thickness and brain infarction: the Etude du Profil Genetique de l’Infarctus Cerebral (GENIC) case-control study. The GENIC Investigators. Circulation 2000, 102:313–318. Salonen R, Salonen JT: Determinants of carotid intimamedia thickness: a population-based ultrasonography study in eastern Finnish men. J Intern Med 1991, 229:225–231. Folsom AR, Wu KK, Shahar E, Davis CE: Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Arterioscler Thromb 1993, 13:1829–1836. Allan PL, Mowbray PI, Lee AJ, Fowkes FG: Relationship between carotid intima-media thickness and symptomatic and asymptomatic peripheral arterial disease. The Edinburgh Artery Study. Stroke 1997, 28:348–353. Bots ML, Hofman A, Grobbee DE: Common carotid intima-media thickness and lower extremity arterial atherosclerosis. The Rotterdam Study. Arterioscler Thromb 1994,14:1885–1891. Salonen R, Nyyssonen K, Porkkala E, et al.: Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995, 92:1758–1764. Blankenhorn DH, Johnson RL, Nessim SA, et al.: The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results. Control Clin Trials 1987, 8:356–387. MacMahon S, Sharpe N, Gamble G, et al.: Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. Circulation 1998, 97:1784–1790. Byington RP, Furberg CD, Crouse JR 3rd, et al.: Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol 1995, 76:54C-59C. Furberg CD, Adams HP Jr, Applegate WB, et al.: Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994, 90:1679–1687. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC: Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 2004, 24:930–934. Koshiyama H, Shimono D, Kuwamura N, et al.: Rapid communication inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001, 86:3452–3456. Brooks MM, Jones RH, Bach RG, et al.: Predictors of mortality and mortality from cardiac causes in the bypass angioplasty revascularization investigation (BARI) randomized trial and registry. For the BARI Investigators. Circulation 2000, 101:2682–2689. Schwartz SM: Perspectives series: cell adhesion in vascular biology. Smooth muscle migration in atherosclerosis and restenosis. J Clin Invest 1997, 99:2814–2816. Osman A, Otero J, Brizolara A, et al.: Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes. Am Heart J 2004, 147:e23. Choi D, Kim SK, Choi SH, et al.: Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004, 27:2654–2660. Takagi T, Yamamuro A, Tamita K, et al.: Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 2003, 146:E5. Sabate M, Jimenez-Quevedo P, Angiolillo DJ, et al.: Diabetes and sirolimus eluting stent trial: The Diabetes Trial. http://www.tctmd.com. Accessed on October 24, 2004. Viberti G, Kahn SE, Greene DA, et al.: A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002, 25:1737–1743. Charbonnel B, Dormandy J, Erdmann E, et al.: The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 2004, 27:1647–1653.